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cardiopulmonary system, we hypothesize that the radiation dose 
delivered to the heart is likely to be an important contributor to the 
development of dyspnea, especially so in patients with cardiac 
comorbidity. Interestingly, while it has been shown that radiation to 
the heart increases the long-term risk of a cardiac event, insufficient 
research has been carried out on the short-term (3-6 months) effects 
of cardiac comorbidity and heart irradiation on the risk of 
radiotherapy-induced lung damage. Does the heart matter for RILT? 
Are there specific cardiac comorbidities associated with a higher 
probability of lung damage? Is there a short-term pulmonary effect 
from (excessive) heart irradiation? These research questions will be 
addressed in the talk, and recent promising evidence on this topic will 
be discussed. 
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Compared to 3D conformal radiotherapy (3DCRT), the advent of 
intensity modulated Radiotherapy (IMRT) for head andneck cancer 
patients (HNC) gave the possibility to dramatically reduce the dose to 
non-involved structures, and this is reported to be correlated to a 
reduced toxicity suffered by the patient. Nevertheless, even with 
IMRT, different toxicities continue to affect the quality of life of HNC 
patients after RT, being xerostomia and dysphagia two of the most 
important. In this context, it could be of particular interest the 
assessment of parameters able to predict individual patient tissue 
reactions during the treatment and possibly the risk of 
developingacute and/or late toxicity. This information could be used 
in order to select patients that may gain advantages by the 
implementation of personalized adaptive treatments and/or 
supportive therapies with the aim of reducing toxicity. 
Structural and volume variations of tissues/organs may be a sign of a 
radiation induced damage and could be measured using different 
image modalities. Image guided RT (IGRT) itself represents a powerful 
database of computed tomography (CT) images acquired during the 
treatment course, that in principle could be used to derive 
information regarding the tissues and organs reaction; also diagnostic 
CTs collected during the treatment for adaptive re-planning are 
another important source of available, high-quality CT information. 
Organs at risk (OAR) in HN region, such as parotid glands (PGs) or 
constrictor muscles, are known to undergo large volume and shape 
changes during RT treatments (that can be easily detected by CT-
images acquired during IGRT), and this is reported to be related to 
organ dysfunction. For example, PGs are known to shrink during HN 
treatment. In literature it is reported that the volume reduction at 
the end of therapy of 30-35 fractions/45 days is around 30-35%. 
On the other hand, density variation of organs during the treatment 
course may be considered as a surrogate of changes in tissue structure 
and therefore a potential measure of a radiation induced functional 
damage. Based on CT-images, it is possible to directly measure  
density variations in terms of Hounsfield units (HU) difference 
between images acquired during the treatment course. Focusing on 
PGs, recent hystopathological studies of tissue samples showed a 
reduction of the acinar cells number, with a relative increase of fat 
component in irradiated PGs compared to not irradiated, and this data 
is likely to be measured by CT-based density variation. Consistently, 
PGs density variation was found to vary significantly during the RT 
course in a large population of patients treated with IMRT; the largest 
variation was found during the first half part of the treatment 
compared to end (p-value=0.0001). Moreover, the early PGs 
density/volume variations, i.e.during the first two weeks of 
treatment, were found to be good predictors of the final changes at 
the end of the therapy (AUC>0.75, p-value=0.0001). Importantly, the 
median early PGs density variation resulted to be significantly 
different for a group of 25 patients with a prospectively assessed 
acute xerostomia score (CTC v3.0) during the treatment course. 
CT-based biomarkers assessed during the RT treatment course, such as 
volume, density and texture parameters, should be considered as 
promising scores which are likely to be surrogates of organ damage 
and consequently related to the probability risk to develop acute 
and/or late toxicity. 
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Purpose/Objective: Volumetric modulated arc therapy (VMAT) 
enables efficient delivery of highly conformal doses, but intrafraction 
tumor motion may lead to target dose distributions that differ 
markedly from the planned dose. The aim of this study was to 
measure the 3D target motion by continuous kV imaging during liver 
SBRT treatments delivered by VMAT and to reconstruct the actual 
target dose by use of the monitored motion. 
Materials and Methods: Five patients with liver metastasis and 2-3 
implanted gold markers received SBRT in three fractions of 18.75Gy or 
25Gy. The CTV was delineated on the mid-ventilation phase of a 4DCT 
scan. Margins of 5 mm in the axial plane and 10 mm in the sup-inf 
directions were added to form the PTV. A VMAT plan with 5-6 arcs was 
designed to give minimum target doses of 95% (CTV) and 67% (PTV). 
Abdominal compression was used for all patients. Daily cone-beam CT 
was used for marker based patient setup and continuous kV images 
(5Hz) and MV images (8-13 Hz) were acquired during treatment 
delivery with an On-Board Imager and an AS500 or AS1000 PortalVision 
system, respectively (Varian). Offline, the intra-treatment 3D 
trajectory of one gold marker was estimated from its projected 2D 
trajectory in the kV images by a probability based method. For three 
patients (those with coplanar arcs and high resolution MV imaging 
(AS1000)) the marker was segmented in all MV images with marker 
visibility at one fraction, which provided an independent measure of 
the kV 3D position estimation error. For all fractions the 3D marker 
motion was used to reconstruct the delivered target dose by a 
previously validated method that mimicks target motion by dividing 
the VMAT beams into sub-beams with different isocenter shifts and 
uses Eclipse (Varian) for dose calculation. The dose reconstruction 
included interplay effects and physical path length changes, but not 
target deformations or shifts relative to the gold marker. The 
reduction in D95 (minimum dose to 95% of the CTV) relative to the 
planned D95 was calculated for all fractions. 
 
 
Results: The gold marker was visible in all kV images and in 32% of the 
MV images. The MV images showed that the kV 3D position estimation 
had mean rms errors of 0.36 mm and 0.55 mm in the resolved and 
unresolved directions of the kV imager, respectively. Fig A shows the 
